Gefitinib 내성 후 Erlotinb과 한방 치료를 병행하여 호전된 뇌전이를 동반한 재발성 L858R 변이 비소세포폐암 환자 1례
A Case Report of Recurrent L858R Mutation Non-Small-Cell Lung Cancer with Brain Metastases Treated with Erlotinib and Traditional Korean Medicine After Failure with Gefitinib
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The purpose of this study is to report the case of a patient with recurrent L858R mutation non-small-cell lung cancer with brain metastases treated with erlotinib and traditional Korean medicine after gefitinib failure. Methods: The patient was treated with erlotinib beginning in November 2021, and gamma knife surgery was performed on November 8, 2021. The dose of erlotinib was 150 mg/day every four weeks. At the same time, the patient was treated with traditional Korean medicine. Tumor size and cerebral edema were measured using computed tomography and magnetic resonance imaging, respectively. Adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Results: After treatment with erlotinib and traditional Korean medicine for six months, the extent of the growing nodule in the right upper lobe decreased during the first three months and remained stable for the following three months. Peritumoral edema showed an increase three months after gamma knife surgery, but partial improvement of cerebral edema was confirmed with additional traditional Korean medicine six months after gamma knife surgery. The symptoms of discomfort and physical activity gradually improved. Conclusions: This case study suggests that the combination of EGFR-TKI and traditional Korean medicine may contribute to a reduction in tumor size and cerebral edema while improving quality of life.
Abstract
Objectives: The purpose of this study is to report the case of a patient with recurrent L858R mutation non-small-cell lung cancer with brain metastases treated with erlotinib and traditional Korean medicine after gefitinib failure. Methods: The patient was treated with erlotinib beginning in November 2021, and gamma knife surgery was performed on November 8, 2021. The dose of erlotinib was 150 mg/day every four weeks. At the same time, the patient was treated with traditional Korean medicine. Tumor size and cerebral edema were measured using computed tomography and magnetic resonance imaging, respectively. Adverse events were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Results: After treatment with erlotinib and traditional Korean medicine for six months, the extent of the growing nodule in the right upper lobe decreased during the first three months and remained stable for the following three months. Peritumoral edema showed an increase three months after gamma knife surgery, but partial improvement of cerebral edema was confirmed with additional traditional Korean medicine six months after gamma knife surgery. The symptoms of discomfort and physical activity gradually improved. Conclusions: This case study suggests that the combination of EGFR-TKI and traditional Korean medicine may contribute to a reduction in tumor size and cerebral edema while improving quality of life.
참고문헌 (32)
- "2020년 통계청 사망원인통계(국가승인통계 제101054호)( 2021년 9월 발표)", ~ (2021)
- "2021년 국가암등록사업 연례 보고서 (2019년 암등록통계)", file:, pp.C:, Users[DOI]
- 김정선, "비소세포폐암의 표적 치료", 대한내과학회지, 95(2), pp.78~88 (2020), 대한내과학회[DOI]
- "가톨릭대학교 서울성모병원 종양내과 강진형 교수 인터뷰. 2018.01.10"[URL]
- Song SY, "Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer", Doctor, Department of Internal Medicine, pp.2022
- Sohaib A, "RECIST rules", Cancer Imaging, 12(2), pp.345~346 (2012)
- Watanabe H, "New Response Evaluation Criteria in Solid Tumours-Revised RECIST Guideline(version 1.1)", Cancer &chemotherapy, 36(13), pp.2495~2501 (2009)
- "Common Terminology Criteria for Adverse Events (CTCAE)" (2020)[URL]
- National Comprehensive Cancer Network, "Non-Small Cell Lung Cancer Metastatic", ~ (2021)
- 최지연, "응급실에서 높은 혈중 D-dimer 수치를 보이는 질환의 CT 소견", 대한영상의학회지, 66(1), pp.93~103 (2012), 대한영상의학회
- "NSCLC(비소세포폐암) 개요 및 치료제 동향", ~ (2021)
- %20131%ED%98%B8_nsclc(%EB%B9%84%EC%86%8C%EC%84%B8%ED%8F%AC%ED%8F%90%EC%95%94)%20%EA%B0%9C%EC%9A%94%20%EB%B0%8F%20%EC%B9%98%EB%A3%8C%EC%A0%9C%20%EB%8F%99%ED%96%A5_final.pdf, , ~
- Hideharu K, "A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment", Cancer Commun(Lond), 39, pp.67~ (2019)
- Singh N, "Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature", World J Clin Oncol, 5(5), pp.858~864 (2014)
- 조경민, "Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure", The Korean Journal of Internal Medicine, 30(6), pp.891~898 (2015), 대한내과학회[DOI]
- Zhang Y, "Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer : A Meta-Analysis", PLOS ONE, 9(9), pp.e107161~ (2014)
- Liang H, "The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy : a literaturebased pooled analysis", J Thorac Dis, 10(4), pp.2311~2320 (2018)
- 정현정, "폐암 환자의 치료 및 관리에서 한의학적 치료의 역할", 대한암한의학회지, 20(1), pp.45~54 (2015), 대한암한의학회
- 양정민, "Casodex", Nolvadex와 한방치료를 병행하여 호전된 재발성 침샘관암 환자 1례, 2021, pp.42(5), 1062~1073[DOI]
- Jeong TY, "Prospective Analysis on Survival Outcomes of Nonsmall Cell Lung Cancer Stages over IIIb Treated with HangAm-Dan", Chin J Lung Cancer, 13(11), pp.1009~1015 (2010)
- 김정훈, "십전대보탕의 면역활성에 관한 기초 실험 연구 문헌 분석", 동의생리병리학회지, 26(5), pp.641~649 (2012), 한의병리학회
- 박동일, "십전대보탕이 알레르기반응에 미치는 영향", 동의생리병리학회지, 17(2), pp.308~315 (2003), 한의병리학회
- Osamu S, "Jyuzen-taiho-to as a Treatment for Pruritus Cutaneous Senilis", Japanese journal of oriental medicine, 50(5), pp.877~881 (2000)
- Jung I, "Overview of Salvia miltiorrhiza as a Potential Therapeutic Agent for Various Diseases: An Update on Efficacy and Mechanisms of Action", Antioxidants (Basel), 9(9), pp.857~ (2020)
- Song JH, "Effects of Salviae Miltiorrhizae Radix on Brain Edema", Master, pp.2010
- 박창훈, "丹蔘이 뇌조직출혈 흰쥐의 혈액뇌관문 손상에 미치는 영향", 대한본초학회지, 29(1), pp.19~26 (2014), 대한본초학회
- 박용기, "三七根의 LPS에 의해 활성화된 腦神經膠細胞로부터의 炎症媒介物質 生成抑制效果", 대한본초학회지, 21(4), pp.93~101 (2006), 대한본초학회
- 장권준, "Crizotinib과 한방치료를 병행하여 호전된 ROS1 양성 재발성 폐암 환자 1례", 대한한방내과학회지, 42(5), pp.820~832 (2021), 대한한방내과학회[DOI]
- Harat M, "Evaluation of Brain Edema Formation Defined By MRI After LINAC-based Stereotactic Radiosurgery", Radiol Oncol, 51(2), pp.137~141 (2017)
- "Gamma Knife for Brain Tumors: Latest Developments and What’s on the Horizon. Two stereotactic radiosurgery experts take stock after Cleveland Clinic’s 10,000th case. Apr. 28, 2022 / Neurosciences / Brain Tumor -"[URL]
- Deng Y, "The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer", Mol Clin Oncol, 2(1), pp.116~120 (2014)
- "식약처 임상시험 정보검색"[URL]